Effect of @entity38763 on cerebral blood flow and neurologic outcome when administered after complete @entity2806 in XXXX .

@entity2806 @entity63 @entity235 @entity26 @entity16 @entity450 @entity38763 @entity460
This study tested the hypothesis that @entity38763 , a @entity460 entry blocking drug, will improve post- @entity63 neurologic outcome when administered after a period of complete @entity2806 , and that the improvement in outcome is related to an increase in post- @entity63 cerebral blood flow (CBF). @entity2806 was produced in 31 @entity235 by temporary ligation of the aorta and venae cavae. In six @entity235 , 10 min of complete @entity2806 was followed by an infusion of @entity38763 1.0 mg X kg-1 iv over 10 min. CBF and cerebral metabolic rate for @entity26 (CMRO2) were measured pre- @entity63 , and for 90 min post- @entity63 . The results from these six @entity235 were compared with results previously obtained from eight untreated @entity235 under similar, but not identical, conditions. The CBF measured post- @entity63 in the @entity235 administered @entity38763 did not differ from the CBF measured post- @entity63 in the untreated @entity235 . Both groups showed an initial @entity450 post- @entity63 , followed by significant decreases in CBF from control values by 35 min post- @entity63 . The post- @entity63 CMRO2 also did not differ between @entity38763 treated and untreated groups. In 25 @entity235 , 11 min of complete @entity2806 was followed by an iv infusion of either @entity38763 1.0 mg X kg-1 or saline placebo. The same iv infusions were repeated at 8 and 16 h post- @entity63 . Seven @entity235 were excluded from data analysis for failure to meet pre-established protocol criteria. @entity16 was evaluated in the remaining @entity235 at 48 h post- @entity63 by an observer blinded to the treatment groups.(ABSTRACT TRUNCATED AT 250 WORDS)
